ATP14 Antibody

What is ATP14 and what is its biological function?

ATP14 (also known as ATP synthase subunit H) is a component of the F1F0-ATP synthase complex, which is critical for cellular energy production. It functions within mitochondrial ATP synthesis pathways, helping to produce ATP from ADP in the presence of a proton gradient across the membrane generated by electron transport complexes of the respiratory chain . The protein plays a structural role in maintaining the proper assembly and function of the ATP synthase complex, particularly in organisms like Schizosaccharomyces pombe where it has been well-characterized .

What types of ATP14 antibodies are currently available for research?

Based on current research tools, ATP14 antibodies are available as polyclonal antibodies raised in rabbits against recombinant proteins. For example, one commercially available antibody (CSB-PA528867XA01SXV) is raised against recombinant Schizosaccharomyces pombe ATP14 protein . Unlike some other mitochondrial protein antibodies like ATP5A (which has well-established monoclonal options like clone 15H4C4), ATP14-specific antibodies tend to be primarily polyclonal, offering different advantages in terms of epitope recognition .

What are the recommended storage conditions for ATP14 antibody?

ATP14 antibodies should be stored at -20°C or -80°C upon receipt. Repeated freeze-thaw cycles should be avoided as they can degrade the antibody and reduce its effectiveness . Most ATP14 antibodies are provided in storage buffers containing glycerol (approximately 50%), PBS (0.01M, pH 7.4), and preservatives like Proclin 300 (0.03%) to maintain stability and prevent microbial growth .

What applications is ATP14 antibody validated for?

ATP14 antibodies have been primarily validated for ELISA and Western blot (WB) applications . These applications allow researchers to detect and quantify ATP14 protein in various sample types. While other applications like immunohistochemistry (IHC) and immunofluorescence may be possible, they typically require additional validation beyond the manufacturer's guaranteed applications.

How should I optimize Western blot protocols for ATP14 antibody?

For optimal Western blot results with ATP14 antibody:

• Sample preparation: Extract proteins using buffers containing appropriate protease inhibitors to prevent degradation of mitochondrial proteins.

• Protein loading: Load 20-40 μg of total protein per lane for cell lysates; adjust based on expression levels.

• Separation: Use 10-12% SDS-PAGE gels for optimal resolution of ATP14.

• Transfer: Transfer proteins to PVDF or nitrocellulose membranes (0.45 μm pore size recommended).

• Blocking: Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody: Dilute ATP14 antibody according to manufacturer's recommendations (typically 1:500-1:2000) and incubate overnight at 4°C.

• Secondary antibody: Use appropriate HRP-conjugated secondary antibody (anti-rabbit IgG for polyclonal ATP14 antibodies) .

• Detection: Develop using ECL substrate and adjust exposure time to optimize signal-to-noise ratio.

Similar to approaches used with other mitochondrial protein antibodies like ATP5A, careful optimization of these parameters will ensure reliable detection of ATP14 .

What controls should I include when working with ATP14 antibody?

When designing experiments with ATP14 antibody, include the following controls:

• Positive control: Samples known to express ATP14 (e.g., wildtype yeast lysates for S. pombe ATP14 antibodies) .

• Negative control: Samples where ATP14 is absent or knocked down (e.g., ATP14 knockout or knockdown cell lines).

• Loading control: Use established mitochondrial markers like ATP5A or other mitochondrial proteins to normalize for mitochondrial content .

• Antibody controls: Include a no-primary antibody control to assess non-specific binding of secondary antibody.

• Blocking peptide control: If available, pre-incubate the antibody with its immunogen peptide to confirm specificity.

These controls help validate results and troubleshoot issues that may arise during experimentation.

How can I validate the specificity of my ATP14 antibody?

Validating antibody specificity is crucial for reliable experimental results. For ATP14 antibody:

• Western blot analysis: Confirm a single band at the expected molecular weight for ATP14.

• Knockdown/knockout validation: Compare signal between wildtype and ATP14-depleted samples.

• Mass spectrometry validation: Following immunoprecipitation with ATP14 antibody, confirm pulled-down proteins by mass spectrometry.

• Cross-reactivity testing: Test antibody against samples from multiple species if working with model organisms.

• Epitope mapping: If repeated specificity issues occur, consider epitope mapping to identify exactly which region of ATP14 the antibody recognizes.

Similar validation approaches have been successful with other mitochondrial protein antibodies, ensuring experimental reliability .

How can ATP14 antibody be used to study mitochondrial dysfunction in disease models?

ATP14 antibody can be a valuable tool for investigating mitochondrial dysfunction:

• Expression level analysis: Quantify ATP14 expression changes in disease models using Western blot or ELISA.

• Subcellular localization: Use immunofluorescence with ATP14 antibody alongside other mitochondrial markers to assess changes in mitochondrial morphology and ATP14 localization.

• Complex assembly assessment: Combine with Blue Native PAGE to evaluate ATP synthase complex assembly and integrity in disease states.

• Protein-protein interactions: Use co-immunoprecipitation with ATP14 antibody to identify altered protein interactions in pathological conditions.

• Tissue distribution: Apply immunohistochemistry to assess tissue-specific changes in ATP14 expression in disease models.

This approach parallels methods used with other mitochondrial proteins like ATP5A, which has been extensively studied in disease contexts .

How can I optimize immunoprecipitation protocols using ATP14 antibody?

For successful immunoprecipitation with ATP14 antibody:

• Lysis buffer selection: Use mild lysis buffers (e.g., NP-40 or digitonin-based) to preserve protein-protein interactions.

• Pre-clearing: Pre-clear lysates with protein A/G beads to reduce non-specific binding.

• Antibody coupling: Consider covalently coupling ATP14 antibody to beads to prevent antibody co-elution.

• Incubation conditions: Optimize antibody-to-protein ratio and incubation time (typically 2-4 μg antibody per 500 μg protein, incubated overnight at 4°C).

• Washing stringency: Balance between removing non-specific interactions and preserving specific ones by testing different wash buffers.

• Elution method: Choose between denaturing (SDS buffer) or non-denaturing (competing peptide) elution based on downstream applications.

This methodology applies principles similar to those used for other mitochondrial protein antibodies in protein interaction studies .

What considerations are important when developing multi-parameter flow cytometry panels including ATP14?

When incorporating ATP14 antibody into multi-parameter flow cytometry:

• Cell permeabilization: Optimize fixation and permeabilization protocols to allow antibody access to mitochondrial proteins while preserving other markers.

• Fluorophore selection: Choose fluorophores with minimal spectral overlap to other panel markers.

• Titration: Carefully titrate ATP14 antibody to determine optimal concentration for signal-to-noise ratio.

• Compensation controls: Include single-stained controls for each fluorophore.

• Gating strategy: Develop a hierarchical gating strategy that accounts for changes in mitochondrial parameters.

• Viability discrimination: Include viability dyes to exclude dead cells, which can have altered mitochondrial parameters.

These approaches have been validated with other mitochondrial markers like ATP5A in flow cytometry applications .

What are common causes of weak or absent signals when using ATP14 antibody in Western blotting?

When troubleshooting weak or absent ATP14 signals:

• Protein degradation: Ensure complete protease inhibition during sample preparation.

• Inefficient transfer: Optimize transfer conditions for mitochondrial proteins (which can be hydrophobic).

• Antibody concentration: Try increasing primary antibody concentration or incubation time.

• Detection sensitivity: Use more sensitive detection reagents or increase exposure time.

• Antibody quality: Check antibody viability; avoid repeated freeze-thaw cycles .

• Sample loading: Ensure adequate protein loading (30-50 μg total protein may be necessary).

• Sample denaturing: For membrane proteins like ATP14, complete denaturation is critical; consider adding additional reducing agents.

• Epitope masking: Different lysis conditions may expose the epitope more effectively.

Similar troubleshooting approaches have proven effective with other mitochondrial antibodies like ATP5A .

How can I address high background when using ATP14 antibody?

To reduce high background with ATP14 antibody:

• Blocking optimization: Test different blocking agents (BSA, milk, commercial blockers) and concentrations.

• Antibody dilution: Increase the dilution of primary and secondary antibodies.

• Wash conditions: Extend wash steps or increase detergent concentration in wash buffers.

• Secondary antibody selection: Ensure secondary antibody is appropriate for the host species of ATP14 antibody.

• Filter antibody solution: Pre-filter antibody solutions to remove aggregates that can cause non-specific binding.

• Fresh reagents: Use freshly prepared buffers and blocking solutions.

• Cross-adsorbed secondaries: Use highly cross-adsorbed secondary antibodies to reduce non-specific binding.

These approaches parallel successful background reduction strategies for other antibodies like ATP5A .

How should I interpret conflicting results between different detection methods using ATP14 antibody?

When faced with conflicting results:

• Method-specific limitations: Different techniques (WB, IF, IHC) have different sensitivities and can detect different conformations of ATP14.

• Sample preparation effects: Different preparation methods may affect epitope accessibility.

• Antibody specificity in context: The antibody may have different specificities under different experimental conditions.

• Quantitative vs. qualitative assessment: Consider whether discrepancies are qualitative or quantitative.

• Validation approach: Use orthogonal methods (e.g., mass spectrometry, RT-PCR) to validate findings.

• Biological variability: Consider whether differences reflect true biological variability rather than technical issues.

Apply these analytical frameworks when interpreting potentially conflicting data from ATP14 experiments.

What experimental designs are appropriate for studying ATP14's role in mitochondrial function?

Robust experimental designs for ATP14 studies include:

• Genetic manipulation approaches:

  • CRISPR/Cas9 knockout or knockdown of ATP14

  • Overexpression studies with tagged ATP14 constructs

  • Site-directed mutagenesis to study functional domains

• Functional assays:

  • ATP synthesis rate measurements

  • Oxygen consumption rate analysis

  • Mitochondrial membrane potential assessments

  • Blue Native PAGE for complex assembly analysis

• Interaction studies:

  • Co-immunoprecipitation followed by mass spectrometry

  • Proximity labeling techniques (BioID, APEX)

  • FRET or BiFC to study dynamic interactions

• Combining techniques:

  • Correlative light and electron microscopy

  • Multi-omics approaches (proteomics, metabolomics)

These experimental designs have been successfully applied in studies of mitochondrial proteins and can be adapted specifically for ATP14 .

Table 1: Comparison of ATP14 Antibody Applications with Other Mitochondrial Marker Antibodies

How does the performance of ATP14 antibody compare to other mitochondrial marker antibodies?

When comparing ATP14 antibody to other mitochondrial markers:

• Specificity considerations: ATP14 antibody tends to be more specific to particular species like S. pombe compared to ATP5A antibodies which have broader cross-reactivity across human, mouse, and rat samples .

• Application versatility: ATP5A antibodies are validated across more applications (western blotting, IHC, immunofluorescence, flow cytometry) compared to ATP14 antibodies which are primarily validated for ELISA and western blotting .

• Clone availability: ATP5A has well-established monoclonal options like clone 15H4C4, while ATP14 antibodies are primarily available as polyclonal reagents .

• Research utility: ATP14 provides specific information about ATP synthase subunit H, while ATP5A targets the catalytic α-subunit of the F1 portion, offering different insights into mitochondrial function and ATP synthase assembly.

Understanding these differences is crucial for selecting the appropriate antibody based on experimental requirements and research questions.